trading: Novellus Systems Inc.(NVLS)
Advisors' Opinion:- [By Lisa Levin]
Nivalis Therapeutics Inc (NASDAQ: NVLS) shares dropped 59 percent to $2.58 after the company reported it failed to demonstrate benefit in absolute change in predicted FEV1 or in Sweat Chloride Reduction at 12 weeks. The failed trial has prompted four Wall Street firms to downgrade the issue including Raymond James, Cowen, Baird and Stifel.
- [By Chris Lange]
Nivalis Therapeutics, Inc. (NASDAQ: NVLS) is watching its shares crumble on Tuesday after the company gave an update on its mid-stage Cystic Fibrosis (CF) trial. Specifically, the company announced topline results from the its Phase 2 trial evaluating the efficacy and safety of two doses of cavosonstat, in adult patients with CF who had two copies of the F508del-CFTR mutation and were being treated with Orkambi.
- [By Chris Lange]
Nivalis Therapeutics Inc. (NASDAQ: NVLS) was recently named as one of Stifel’s three stocks thatcould double. Shares closed at $6.38. The consensus price target is$25.00, and the52-week range is$5.89 to $6.60.
source from Top Stocks For 2015:http://www.topstocksblog.com/trading.html
